Dyrskjot Lars, Zieger Karsten, Orntoft Torben Falck
Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark.
Front Biosci. 2007 Jan 1;12:2063-73. doi: 10.2741/2211.
Bladder cancer is the fifth most common neoplasm in industrialized countries. Due to frequent recurrences of the superficial form of this disease, bladder cancer ranks as one of the most common cancers. Despite the description of a large number of tumor markers for bladder cancers, none have individually contributed to the management of the disease. However, the development of high-throughput techniques for simultaneous assessment of a large number of markers has allowed classification of tumors into clinically relevant molecular subgroups beyond those possible by pathological classification. Here, we review the recent advances in high-throughput molecular marker identification for superficial and invasive bladder cancers.
膀胱癌是工业化国家中第五大常见肿瘤。由于这种疾病的浅表形式频繁复发，膀胱癌跻身最常见癌症之列。尽管已描述了大量用于膀胱癌的肿瘤标志物，但没有一种能单独对该疾病的管理起到作用。然而，用于同时评估大量标志物的高通量技术的发展，已使肿瘤能够被分类为临床相关的分子亚组，这超出了病理分类所能做到的范围。在此，我们综述了浅表性和浸润性膀胱癌高通量分子标志物鉴定方面的最新进展。
